The p202 Gene as a Tumor Suppressor in Prostate Cancer Cells
Abstract
During the funding period (June Ol - May 05), we have completed the most Aims and subaims proposed in the proposal, i.e. to determine the anti-tumor and the pro-apoptotic activities of p202 in prostate cancer cells; to understand the molecular mechanisms underlying the p202-mediated anti-growth, anti-tumor, and potential pro-apoptosis activities in prostate cancer; and to test the anti-tumor activity of p202 in prostate cancer cells using preclinical gene therapy strategies and to determine the efficacy of a combined treatment with TN F-alpha in an orthotopic prostate cancer model. In an attempt to initiate a p202 clinical trial, we have communicated with the FDA and been informed that the human gene is preferable over murine one. Therefore, we have proceeded to clone a human counterpart of p202 gene, the AIM2 (absent in melanoma). We have obtained encouraging results on AIM2 that has the similar effect of p202 in anti-growth activity in prostate cancer cells in cell culture, and exhibits an anti-tumor growth activity in animals bearing mammary tumors. To further extend the specificity for both androgen receptor-positive and -refractory prostate cancers, we have newly developed a broad spectrum of robust prostate cancer-specific expression vector. We intend to test the therapeutic efficacy and specificity by using the broad spectrum of prostate cancer-specific promoter to drive the therapeutic gene, AIM2 in animals. In an attempt to discover more novel strategies to treat prostate cancer, emodin, which has shown a promising killing effect on prostate cancer cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2005
- Accession Number
- ADA442242
Entities
People
- Mien-Chie Hung
Organizations
- University of Texas at Austin